ACRV
Acrivon Therapeutics, Inc. Common Stock NASDAQ Listed Nov 15, 2022$1.57
+3.29%
vs $1.52
Mkt Cap $60.5M
52w Low $1.18
21.3% of range
52w High $3.01
50d MA $1.72
200d MA $1.85
P/E (TTM)
-0.8x
EV/EBITDA
—
P/B
0.5x
Debt/Equity
0.0x
ROE
-69.2%
P/FCF
-0.9x
RSI (14)
47.50
ATR (14)
$0.09
Beta
1.74
50d MA
$1.72
200d MA
$1.85
Avg Volume
417.3K
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response and cell cycle regulation pathways, such as WEE1, a protein kinase and PKMYT1, a protein serine/threonine kinase. The company was incorporated in 2018 and is based in Watertown, Massachusetts.
480 Arsenal Way · Watertown, MA 02472 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 19, 2026 | AMC | -0.49 | -0.49 | +0.0% | 1.70 | -0.6% | -2.4% | -3.6% | -1.2% | -3.8% | -6.6% | — |
| Nov 13, 2025 | AMC | -0.57 | -0.47 | +17.5% | 2.07 | -2.9% | +8.2% | +6.2% | +2.1% | -2.9% | -4.2% | — |
| Aug 13, 2025 | AMC | -0.57 | -0.55 | +3.5% | 1.31 | +4.6% | +6.1% | -2.9% | +3.0% | -6.5% | +0.0% | — |
| May 14, 2025 | AMC | -0.57 | -0.51 | +10.5% | 1.14 | +0.0% | -3.5% | +4.5% | +2.6% | +5.9% | -8.0% | — |
| Mar 27, 2025 | AMC | -0.69 | -0.60 | +13.0% | 2.52 | -1.6% | -11.1% | -9.4% | -17.2% | +3.6% | -5.7% | — |
| Nov 13, 2024 | AMC | -0.56 | -0.59 | -5.4% | 7.93 | +0.3% | -0.1% | -12.1% | -9.9% | +1.8% | +1.9% | — |
| Aug 13, 2024 | AMC | -0.59 | -0.52 | +11.9% | 7.25 | +1.4% | -3.2% | +3.0% | +5.1% | +9.6% | +8.4% | — |
| May 14, 2024 | AMC | -0.89 | -0.73 | +18.0% | 8.36 | +2.6% | +3.5% | -1.0% | +3.9% | -3.8% | -4.0% | — |
| Mar 28, 2024 | AMC | -0.72 | -0.86 | -19.4% | 7.15 | -0.8% | +1.4% | -7.7% | -0.4% | +0.5% | -3.1% | — |
| Nov 9, 2023 | AMC | -0.72 | -0.66 | +8.3% | 4.59 | +4.4% | -4.7% | +4.2% | +11.4% | +2.2% | -14.5% | — |
| Aug 11, 2023 | AMC | -0.68 | -0.63 | +7.4% | 12.39 | -2.3% | -3.1% | -2.4% | -3.9% | -2.0% | +0.8% | — |
| May 9, 2023 | AMC | -0.60 | -0.58 | +3.3% | 13.57 | +4.1% | -4.2% | +4.5% | -1.0% | +4.8% | -1.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 9 | Piper Sandler | Maintains | Overweight → Overweight | — | $1.93 | $1.95 | +1.0% | -9.3% | -6.9% | +4.3% | +7.6% | +2.2% |
| Nov 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.36 | $2.37 | +0.4% | -1.7% | +1.7% | +0.0% | +2.5% | -9.1% |
| Aug 14 | Oppenheimer | Maintains | Outperform → Outperform | — | $1.31 | $1.37 | +4.6% | +6.1% | -2.9% | +3.0% | -6.5% | +0.0% |
| May 16 | Jones Trading | Downgrade | Buy → Hold | — | $1.10 | $1.12 | +1.8% | +4.5% | +2.6% | +5.9% | -8.0% | +0.0% |
| May 15 | Oppenheimer | Maintains | Outperform → Outperform | — | $1.14 | $1.14 | +0.0% | -3.5% | +4.5% | +2.6% | +5.9% | -8.0% |
| Mar 28 | Oppenheimer | Maintains | Outperform → Outperform | — | $2.52 | $2.48 | -1.6% | -11.1% | -9.4% | -17.2% | +3.6% | -5.7% |
| Mar 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.52 | $2.48 | -1.6% | -11.1% | -9.4% | -17.2% | +3.6% | -5.7% |
| Mar 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.39 | $4.26 | -21.0% | -51.6% | -3.4% | -11.1% | -9.4% | -17.2% |
| Mar 26 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $5.39 | $4.26 | -21.0% | -51.6% | -3.4% | -11.1% | -9.4% | -17.2% |
| Mar 26 | Citizens Capital Markets | Maintains | Market Outperform → Market Outperform | — | $5.39 | $4.26 | -21.0% | -51.6% | -3.4% | -11.1% | -9.4% | -17.2% |
| Nov 14 | BMO Capital | Maintains | Outperform → Outperform | — | $7.93 | $7.95 | +0.3% | -0.1% | -12.1% | -9.9% | +1.8% | +1.9% |
| Nov 14 | HC Wainwright& Co. | Maintains | Buy → Buy | — | $7.93 | $7.95 | +0.3% | -0.1% | -12.1% | -9.9% | +1.8% | +1.9% |
| Nov 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.93 | $7.95 | +0.3% | -0.1% | -12.1% | -9.9% | +1.8% | +1.9% |
| Sep 16 | BMO Capital | Maintains | Outperform → Outperform | — | $8.91 | $9.50 | +6.6% | -7.6% | -7.7% | -0.5% | +0.4% | -1.6% |
| Sep 16 | Ladenburg Thalmann | Upgrade | Neutral → Buy | — | $8.91 | $9.50 | +6.6% | -7.6% | -7.7% | -0.5% | +0.4% | -1.6% |
| Sep 16 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $8.91 | $9.50 | +6.6% | -7.6% | -7.7% | -0.5% | +0.4% | -1.6% |
| Sep 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.91 | $9.50 | +6.6% | -7.6% | -7.7% | -0.5% | +0.4% | -1.6% |
| Aug 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.59 | $7.66 | +0.9% | -4.5% | -3.2% | +3.0% | +5.1% | +9.6% |
| May 15 | BMO Capital | Maintains | Outperform → Outperform | — | $8.36 | $8.58 | +2.6% | +3.5% | -1.0% | +3.9% | -3.8% | -4.0% |
| May 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.48 | $8.32 | -1.9% | -1.4% | +3.5% | -1.0% | +3.9% | -3.8% |
| Apr 29 | Ladenburg Thalmann | Downgrade | Buy → Neutral | — | $8.46 | $8.22 | -2.8% | +18.2% | -9.1% | -9.5% | +2.8% | +13.4% |
| Apr 26 | BMO Capital | Maintains | Outperform → Outperform | — | $8.47 | $8.53 | +0.7% | -0.1% | +18.2% | -9.1% | -9.5% | +2.8% |
| Apr 25 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $9.50 | $9.50 | +0.0% | -10.8% | -0.1% | +18.2% | -9.1% | -9.5% |
| Apr 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.50 | $9.50 | +0.0% | -10.8% | -0.1% | +18.2% | -9.1% | -9.5% |
| Apr 25 | Piper Sandler | Maintains | Overweight → Overweight | — | $9.50 | $9.50 | +0.0% | -10.8% | -0.1% | +18.2% | -9.1% | -9.5% |
| Apr 5 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $6.69 | $6.57 | -1.8% | -3.1% | -8.8% | +62.8% | +8.0% | -10.6% |
| Apr 1 | BMO Capital | Maintains | Outperform → Outperform | — | $7.15 | $7.09 | -0.8% | +1.4% | -7.7% | -0.4% | +0.5% | -3.1% |
| Apr 1 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $7.15 | $7.09 | -0.8% | +1.4% | -7.7% | -0.4% | +0.5% | -3.1% |
| Mar 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.47 | $6.29 | -2.8% | +10.5% | +1.4% | -7.7% | -0.4% | +0.5% |
| Nov 10 | BMO Capital | Maintains | Outperform → Outperform | — | $4.59 | $4.79 | +4.4% | -4.7% | +4.2% | +11.4% | +2.2% | -14.5% |
| Sep 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.10 | $12.09 | -0.1% | -1.7% | -1.7% | -1.7% | +0.8% | -4.8% |
| Aug 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.60 | $11.60 | +0.0% | +6.8% | -3.1% | -2.4% | -3.9% | -2.0% |
No insider trades available.
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
This boilerplate 8-K disclosure safeguards ACRV from liability for voluntary information sharing, but provides no material news about business performance or strategy changes affecting stock valuation.
Mar 19
8-K
Acrivon Therapeutics, Inc. -- 8-K Filing
Acrivon terminated its diagnostic partnership with Quanterix but secured continued clinical testing support during transition to Acrivon's CLIA laboratory for its ACR-368 oncology study.
Mar 2
8-K · 7.01
! Medium
Acrivon Therapeutics, Inc. -- 8-K 7.01: Regulation FD Disclosure
Acrivon Therapeutics disclosed positive interim ACR-368 clinical data for endometrial cancer treatment at a key opinion leader panel, supporting the drug's potential to address unmet serous subtype needs.
Feb 27
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Sands Capital Alternatives, Llc | 2,122,605 | $3M | — | Mar 2026 |
| 2 | Acadian Asset Management Llc | 845,973 | $1M | Added | Mar 2026 |
| 3 | Renaissance Technologies Llc | 758,440 | $1M | Added | Mar 2026 |
| 4 | Vanguard Capital Management Llc | 722,035 | $1M | New | Mar 2026 |
| 5 | Jane Street Group, Llc | 342,071 | $824K | Added | Dec 2025 |
| 6 | Marshall Wace, Llp | 560,436 | $779K | Added | Mar 2026 |
| 7 | Two Sigma Investments, Lp | 389,395 | $541K | Reduced | Mar 2026 |
| 8 | Morgan Stanley | 93,662 | $226K | Reduced | Dec 2025 |
| 9 | Northern Trust Corp | 48,902 | $68K | Reduced | Mar 2026 |
| 10 | Ubs Group Ag | 34,634 | $48K | Reduced | Mar 2026 |
| 11 | Panagora Asset Management Inc | 33,814 | $47K | New | Mar 2026 |
| 12 | Citigroup Inc | 14,592 | $35K | Reduced | Dec 2025 |
| 13 | Prelude Capital Management, Llc | 24,015 | $33K | Reduced | Mar 2026 |
| 14 | Marex Group Plc | 20,000 | $28K | Added | Mar 2026 |
| 15 | Aaf Wealth Management, Llc | 10,678 | $26K | — | Dec 2025 |
| 16 | Bank Of America Corp /de/ | 16,513 | $23K | Reduced | Mar 2026 |
| 17 | Fmr Llc | 9,422 | $13K | Added | Mar 2026 |
| 18 | Barclays Plc | 5,940 | $8K | Reduced | Mar 2026 |
| 19 | Wells Fargo & Company/mn | 3,000 | $4K | New | Mar 2026 |
| 20 | Bnp Paribas Financial Markets | 634 | $881 | — | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 8
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 110,324 | $167K | Feb 2026 |
| 2 | Ultra-Small Company Fund | 116,000 | $161K | Mar 2026 |
| 3 | iShares Micro-Cap ETF | 45,169 | $63K | Mar 2026 |
| 4 | Nationwide Bailard Cognitive Value Fund | 29,799 | $53K | Jan 2026 |
| 5 | Ultra-Small Company Market Fund | 38,000 | $53K | Mar 2026 |
| 6 | Fidelity Series Total Market Index Fund | 24,820 | $37K | Feb 2026 |
| 7 | Fidelity Total Market Index Fund | 24,809 | $37K | Feb 2026 |
| 8 | Fidelity Nasdaq Composite Index Fund | 18,053 | $27K | Feb 2026 |
Valuation
Market Cap
$60.5M
Enterprise Value
-$56.6M
P/E (TTM)
-0.78x
Forward P/E
—
PEG Ratio
0.31x
P/B
0.54x
P/S
—
P/FCF
-0.93x
EV/EBITDA
—
Shares Out
38.5M
Financials (TTM)
Revenue
$0
Net Income
-$77.9M
EBITDA
-$82.8M
Free Cash Flow
-$65.3M
Op Cash Flow
-$63.7M
EPS Basic
$-2.02
EPS Diluted
$-2.02
EPS Forward
$-2.18
Gross Margin
0.0%
Op Margin
0.0%
Net Margin
0.0%
Balance Sheet
Total Assets
$129.7M
Total Liab.
$17.2M
Total Equity
$112.5M
Cash
$118.6M
LT Debt
$1.5M
Book Value/Sh
$2.92
Debt/Equity
0.02x
Current Ratio
7.69
Quick Ratio
7.69
Returns & Growth
ROE
-69.2%
ROA
-60.1%
ROIC
-73.0%
Rev Growth YoY
+0.0%
EPS Growth YoY
+3.8%
Price Returns
2W
-16.7%
1M
-13.5%
3M
+6.0%
6M
-32.2%
12M
+52.4%
Technicals
52W High
$3.01
52W Low
$1.18
50d MA
$1.72
200d MA
$1.85
RSI (14)
47.50
ATR (14)
$0.09
Beta
1.74
Avg Volume
417K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$21.83
High
$30.00
Low
$17.00
Median
$20.00
Data updated apr 24, 2026 10:42am
· Source: financialmodelingprep.com